ACURATE Neo™ TA Delivery System in Patient With Severe Aortic Stenosis
ACURATE Neo™ TA Delivery System in Patient With Severe Aortic Stenosis
The purpose of this investigation is to collect data pertaining to the safety and performance
 of the ACURATE neo (TM) Aortic Bioprosthesis as implanted with the ACURATE neo (TM) TA
 Transapical Delivery System. This device is intended for treatment of subjects with severe
 aortic stenosis (AS) who have high risk for conventional aortic valve replacement (AVR)
 surgery. The ACURATE neo (TM) Aortic Bioprosthesis is intended for use via minimally-invasive
 transapical implantation in a well-defined population.
This is a single arm, prospective, multicenter non randomised and open trial of the treatment
 of patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via
 open heart surgery is considered to be high risk. All patients will be followed up to 5 years
 after the intervention.

 The primary objective is to evaluate the safety and performance of the study device in
 patients presenting with severe aortic stenosis considered to be high risk for surgery
 Secondary objective is to evaluate adverse events and study device performance.
Inclusion Criteria:

 1. Subject must be at least 18 years old

 2. Severe aortic stenosis defined as:

 -  Mean aortic gradient > 40 mmHg or

 -  Peak jet velocity > 4.0 m/s or

 -  Aortic valve area of < 0.8 cm2

 3. High risk patient determined by a multidisciplinary heart team consensus (cardiologist
 and cardiac surgeon) that patient is not a surgical candidate for conventional AVR due
 to risk factors such as STS Score (8% or higher) or other co-morbid conditions
 unrelated to aortic stenosis such as severe chronic obstructive pulmonary disease
 (COPD), chest deformities and irradiated mediastinum

 4. NYHA Functional Class > II

 5. Multidisciplinary heart team (cardiologist and cardiac surgeon) consensus that the
 transapical approach is the most suitable access route for TAVI due to the presence of
 the following anatomic conditions:

 -  porcelain aorta or

 -  severely calcified or highly tortuous peripheral vasculature not appropriate for
 transfemoral transcatheter aortic valve implantation or

 -  vessels too small for retrograde approach or

 -  other anatomical conditions making transapical approach more suitable

 6. Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by CT or TEE

 7. Patient willing to participate in the study and provides signed informed consent

 Exclusion Criteria:

 1. Congenital unicuspid or bicuspid aortic valve or non-calcified

 2. Extreme eccentricity of calcification

 3. Severe mitral regurgitation (> Grade 3)

 4. Pre-existing prosthetic heart valve in any position and / or prosthetic ring

 5. LV apex is not accessible via transapical access due to severe chest deformity

 6. Previous surgery of the LV using a patch, such as the Dor procedure

 7. Presence of apical LV thrombus

 8. Calcified pericardium

 9. Septal hypertrophy unacceptable for transapical procedure

 10. Transesophageal echocardiogram (TEE) is contraindicated

 11. ECHO evidence of intracardiac mass, thrombus, or vegetation

 12. LVEF < 20% by ECHO

 13. Need for emergency intervention for any reason within 30 Days of scheduled procedure

 14. Any percutaneous intervention, except for balloon valvuloplasty (BAV) within 1 month
 prior to implant procedure

 15. Untreated clinically significant coronary artery disease requiring revascularization
 within 30 days before or after the study procedure

 16. Acute myocardial infarction within 1 month prior to implant procedure

 17. Previous TIA or stroke within 6 months prior to implant procedure

 18. Active gastrointestinal (GI) bleeding within 3 months prior to implant procedure

 19. Scheduled surgical or percutaneous procedure to be performed prior to 30 day visit

 20. History of bleeding diathesis, coagulopathy, refusal of blood transfusions or severe
 anemia (Hb<8 g/dL)

 21. Systolic pressure <80mmHg, cardiogenic shock, need for inotropic support or IABP

 22. Primary hypertrophic obstructive cardiomyopathy (HOCM)

 23. Active infection or endocarditis

 24. Hepatic failure (> Child B)

 25. Chronic renal dysfunction with serum creatinine > 3.0 mg/dL or renal dialysis

 26. Neurological disease severely affecting ambulation, daily functioning, or dementia

 27. Life expectancy < 12 months due to non-cardiac co-morbid conditions

 28. Intolerance to aspirin, clopidogrel, contrast media, or porcine tissue and allergy to
 nickel

 29. Pregnant or breast-feeding women

 30. For other severe illnesses of the patient (e.g. active carcinoma), the investigator
 shall decide on an individual basis whether the patient is not to be included in the
 study

 31. Currently participating in an investigational drug or another device study